CN101952422A - 化学修饰的因子ix - Google Patents

化学修饰的因子ix Download PDF

Info

Publication number
CN101952422A
CN101952422A CN2008801232530A CN200880123253A CN101952422A CN 101952422 A CN101952422 A CN 101952422A CN 2008801232530 A CN2008801232530 A CN 2008801232530A CN 200880123253 A CN200880123253 A CN 200880123253A CN 101952422 A CN101952422 A CN 101952422A
Authority
CN
China
Prior art keywords
fix
hydrophilic polymer
water
soluble hydrophilic
serine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801232530A
Other languages
English (en)
Chinese (zh)
Inventor
彼得·图雷切克
弗里德里希·沙伊夫林格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Publication of CN101952422A publication Critical patent/CN101952422A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN2008801232530A 2007-12-27 2008-12-19 化学修饰的因子ix Pending CN101952422A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US926307P 2007-12-27 2007-12-27
US61/009,263 2007-12-27
PCT/EP2008/010925 WO2009083187A1 (en) 2007-12-27 2008-12-19 Chemically modified factor ix

Publications (1)

Publication Number Publication Date
CN101952422A true CN101952422A (zh) 2011-01-19

Family

ID=40344940

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801232530A Pending CN101952422A (zh) 2007-12-27 2008-12-19 化学修饰的因子ix

Country Status (11)

Country Link
US (2) US20090176708A1 (enExample)
EP (4) EP2568043A1 (enExample)
JP (1) JP2011507919A (enExample)
KR (1) KR20100110799A (enExample)
CN (1) CN101952422A (enExample)
AU (1) AU2008342260B2 (enExample)
CA (1) CA2709960A1 (enExample)
IL (1) IL206095A0 (enExample)
NZ (3) NZ603997A (enExample)
RU (1) RU2010131189A (enExample)
WO (1) WO2009083187A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2353588B1 (en) 2010-01-21 2015-04-15 Agricultural Technology Research Institute A sustained release preparation of factor IX
TWI788044B (zh) 2013-03-15 2022-12-21 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
AR099340A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados del factor de coagulación ix
US10772942B2 (en) 2014-03-24 2020-09-15 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
US20220378840A1 (en) * 2019-11-29 2022-12-01 Rutgers, The State University Of New Jersey Compositions, kits and methods for storage of blood products and methods of use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS538750B2 (enExample) 1971-08-18 1978-03-31
AT348548B (de) 1977-04-08 1979-02-26 Laevosan Gmbh & Co Kg Verfahren zur herstellung von alsblutplasma- expander geeignerter hydroxyaethylstaerke
US5614500A (en) 1983-03-04 1997-03-25 The Scripps Research Institute Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography
DE3313600A1 (de) * 1983-04-14 1984-10-18 Laevosan-Gesellschaft mbH & Co. KG, Linz Plasmastreckmittel auf staerkebasis und verfahren zu ihrer herstellung
DE19975071I2 (de) 1989-06-16 2000-02-03 Fresenius Ag Hydroxyethylstaerke als Plasmaexpander Verfahren zu ihrer Herstellung und Verwendung als kolloidales Plasmaersatzmittel
FR2702160B1 (fr) 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
DE4310974C2 (de) * 1993-04-03 1996-08-01 Fresenius Ag Verwendung von Hydroxyethylstärke zur Verbesserung der Mikrozirkulation
FR2704145B1 (fr) 1993-04-21 1995-07-21 Pasteur Institut Vecteur particulaire et composition pharmaceutique le contenant.
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
EP0973544B1 (de) * 1997-04-08 2001-06-27 Baxter Aktiengesellschaft Immuntolerante prothrombinkomplex-präparation
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
EP1620118B1 (en) 2003-04-08 2014-06-18 Yeda Research And Development Co., Ltd. Reversible pegylated drugs
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
EP1694315A4 (en) * 2003-12-03 2009-10-28 Novo Nordisk As FACTOR IX GLYCOPEGYL
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
KR101215226B1 (ko) 2004-03-01 2012-12-26 베. 브라운 멜중엔 악티엔게젤샤프트 하이드록시에틸전분
WO2005092928A1 (en) * 2004-03-11 2005-10-06 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
WO2006018204A1 (en) * 2004-08-17 2006-02-23 Zlb Behring Gmbh Modified vitamin k dependent polypeptides
JP2008532966A (ja) * 2005-03-11 2008-08-21 フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 不活性出発物質からの生理活性糖タンパク質の生成
WO2007101681A1 (en) 2006-03-07 2007-09-13 Baxter International Inc Highly phosphorylated and sulfated recombinant factor ix
CN101454267B (zh) 2006-03-29 2012-09-26 帝斯曼知识产权资产管理有限公司 姜黄素的合成
TW200804416A (en) * 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
EP2155865B1 (en) * 2007-06-15 2014-09-17 National Research Council Of Canada Engineered versions of polysialyltransferases with enhanced enzymatic properties

Also Published As

Publication number Publication date
AU2008342260A1 (en) 2009-07-09
EP2247723A1 (en) 2010-11-10
US20090176708A1 (en) 2009-07-09
NZ598193A (en) 2012-12-21
CA2709960A1 (en) 2009-07-09
JP2011507919A (ja) 2011-03-10
US20120177625A1 (en) 2012-07-12
AU2008342260B2 (en) 2013-10-17
NZ585835A (en) 2012-07-27
NZ603997A (en) 2013-02-22
EP2568043A1 (en) 2013-03-13
EP2568042A1 (en) 2013-03-13
IL206095A0 (en) 2010-11-30
KR20100110799A (ko) 2010-10-13
EP2568041A1 (en) 2013-03-13
RU2010131189A (ru) 2012-02-10
WO2009083187A8 (en) 2009-09-17
WO2009083187A1 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
JP5876208B2 (ja) 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体
JP5619630B2 (ja) 結合型第ｖｉｉｉ因子分子
JP6250282B2 (ja) 出血性障害の治療および予防的治療における非静脈内投与のためのアルブミン融合凝固因子
US20130337532A1 (en) Therapeutic polypeptides with increased in vivo recovery
CN108289851A (zh) 长效凝固因子及其产生方法
US20120177625A1 (en) Chemically modified factor ix

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110119